U.S. markets open in 4 hours 39 minutes
  • S&P Futures

    4,298.25
    0.00 (0.00%)
     
  • Dow Futures

    33,894.00
    +21.00 (+0.06%)
     
  • Nasdaq Futures

    13,682.50
    +1.25 (+0.01%)
     
  • Russell 2000 Futures

    2,025.90
    +2.10 (+0.10%)
     
  • Crude Oil

    88.47
    -0.94 (-1.05%)
     
  • Gold

    1,791.40
    -6.70 (-0.37%)
     
  • Silver

    20.11
    -0.16 (-0.80%)
     
  • EUR/USD

    1.0142
    -0.0023 (-0.22%)
     
  • 10-Yr Bond

    2.7910
    0.0000 (0.00%)
     
  • Vix

    19.97
    +0.44 (+2.25%)
     
  • GBP/USD

    1.2035
    -0.0023 (-0.19%)
     
  • USD/JPY

    133.8500
    +0.5780 (+0.43%)
     
  • BTC-USD

    24,007.54
    -38.46 (-0.16%)
     
  • CMC Crypto 200

    569.83
    -20.93 (-3.54%)
     
  • FTSE 100

    7,542.15
    +33.00 (+0.44%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

Pfizer submits a new NDA to FDA for COVID-19 pill PAXLOVID

·1 min read
Pfizer submits a new NDA to FDA for COVID-19 pill PAXLOVID
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Pfizer Inc. said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness. PAXLOVID has previously been granted Emergency Use Authorization (EUA) for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval. "Data from our clinical development program, coupled with the more than 1.7 million patients around the